How Recent Analyst Shifts And Brinsupri Milestones Are Reframing The Insmed (INSM) Story

Simply Wall St

Thu, February 19, 2026 at 12:14 PM GMT+9 5 min read

In this article:

INSM

+0.39%

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

The latest update to our Insmed narrative shows only a slight reset in the numbers, with the blended fair value estimate edging from about US$215.10 to roughly US$214.37 per share as assumptions around long term revenue growth and the discount rate are nudged closer to where recent Street research is clustering. Behind that small move is a tug of war between bullish analysts, who point to Brinsupri progress and growing institutional interest, and more cautious voices who highlight funding needs, commercialization risk, and sector wide sentiment. Stay with this article to see how you can keep track of these shifting inputs and the evolving story around Insmed from here.

Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Insmed.

What Wall Street Has Been Saying

Recent Street research on Insmed continues to skew constructive, with several firms updating their views and targets in January 2026. Together, these notes feed directly into how analysts are thinking about the risk reward trade off around valuation, execution, and growth potential.

🐂 Bullish Takeaways

Roth Capital and Barclays both initiated coverage with bullish views in January, adding to the group of firms that see sufficient growth potential and execution progress to support constructive stances on the stock.

UBS keeps a Buy rating while adjusting its price target to US$215 from US$223, tying its view to a cautiously optimistic setup for biotech, with potential support from a large pool of pending M&A capital that could help sentiment toward commercial stage names such as Insmed.

Morgan Stanley maintains an Equal Weight rating with a US$157 target and highlights U.S. small to mid cap biotech as a group where commercial companies are seen transitioning from capital consumers to capital producers, which frames how investors might think about Insmed's path to funding its pipeline and commercial efforts.

🐻 Bearish Takeaways

Even among supportive firms, target moves at UBS and Morgan Stanley are slightly lower, which signals some caution around how much upside is already reflected in current expectations and the sector's capital needs.

Morgan Stanley's Equal Weight stance and US$157 target sit below more bullish numbers like the UBS US$215 target. This underscores that some analysts are more guarded on valuation, near term funding dynamics, and execution risk around turning commercial progress into durable cash generation.

 






Story Continues  

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!

NasdaqGS:INSM 1-Year Stock Price Chart

What’s in the News

Insmed issued full year 2025 revenue guidance, with the company expecting total revenues of US$606.4 million compared with US$363.7 million reported a year earlier, giving investors a clearer sense of management's current outlook for the business.

The stock was added to the NASDAQ-100 Index, bringing Insmed into one of the most widely followed large cap benchmarks on the exchange, which can put the name in front of more index and benchmark aware investors.

The Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps did not meet its primary or secondary efficacy endpoints. Insmed has discontinued development of brensocatib for this indication, while reporting that the drug was well tolerated in the trial with no new safety signals identified, including at the 40 mg dose.

Following the BiRCh outcome, Insmed plans to advance Phase 2 programs for INS1148 in interstitial lung disease and in moderate to severe asthma. This keeps attention on the wider pipeline beyond brensocatib in this specific setting.

How This Changes the Fair Value For Insmed

Fair Value: the blended fair value estimate edges down slightly from about US$215.10 to roughly US$214.37 per share, reflecting small tweaks to the underlying assumptions rather than a wholesale shift in the thesis.

Discount Rate: the discount rate assumption trims down a bit from about 7.13% to roughly 7.06%, which modestly increases the present value placed on future cash flows in the model.

Revenue Growth: the long term revenue growth input is adjusted slightly lower from about 97.00% to roughly 96.82%, signaling a very small recalibration of how quickly the top line is expected to scale in the later forecast years.

Net Profit Margin: the modeled net profit margin ticks up from about 23.79% to roughly 23.85%, a small adjustment that assumes slightly greater efficiency in translating revenues into earnings over time.

Future P/E: the future P/E multiple assumption eases slightly from about 84.91x to roughly 84.46x, suggesting a marginally more restrained view on how much investors might be willing to pay for those modeled earnings.

🔔 Never Miss an Update: Follow The Narrative

Narratives on Simply Wall St let you connect Insmed’s story with the numbers by linking a clear viewpoint on the company to forecasts for revenue, earnings and margins, and then to a fair value. They sit inside the Community page, are easy to read, and help you compare fair value to the current share price. As news, clinical data, or earnings arrive, the narrative updates so you can quickly reassess your view without rebuilding your model from scratch.

Head over to the Simply Wall St Community and follow the Insmed narrative to stay on top of what matters most for this story: INSM: European Respiratory Approval And NASDAQ Inclusion Will Support Future Platform Expansion. You will be kept up to date on:

How anticipated U.S. and international brensocatib launches, along with ARIKAYCE label expansion, are built into revenue and earnings forecasts.

What assumptions sit behind the long term profit margin, discount rate and high future P/E multiple used to reach the current fair value for Insmed.

Which clinical, regulatory and payer related risks could challenge the revenue path that underpins the analyst price target range.

Curious how numbers become stories that shape markets? Explore Community Narratives

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include INSM.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info